SERA trades 139.2% below Wall Street's consensus target of $5.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes SERA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 5 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 7, 2026, Sera Prognostics, Inc. (SERA) has a Wall Street consensus price target of $5.00, based on estimates from 5 covering analysts. With the stock currently trading at $2.09, this represents a potential upside of +139.2%. The company has a market capitalization of $80M.
Analyst price targets range from a low of $5.00 to a high of $5.00, representing a 0% spread in expectations. The median target of $5.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SERA trades at a trailing P/E of -3.1x. Analysts expect EPS to grow -5.3% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
NTRANatera, Inc. | $40.6B | $283.80 | $261.00 | -8.0% | Buy | — | 27 |
PGNYProgyny, Inc. | $2.4B | $30.93 | $30.33 | -1.9% | Buy | 23.9x | 20 |
OVIDOvid Therapeutics Inc. | $344M | $2.61 | $5.50 | +110.7% | Buy | — | 14 |
INVAInnoviva, Inc. | $1.6B | $21.82 | $37.00 | +69.6% | Buy | 6.1x | 10 |
ILMNIllumina, Inc. | $29.5B | $194.33 | $156.27 | -19.6% | Buy | 37.1x | 50 |
EXASExact Sciences Corporation | $20.0B | $104.91 | $105.00 | +0.1% | Buy | 582.8x | 41 |
CSTLCastle Biosciences, Inc. | $734M | $24.21 | $42.80 | +76.8% | Buy | — | 11 |
LHLabcorp Holdings Inc. | $23.4B | $284.39 | $311.33 | +9.5% | Buy | 15.8x | 35 |
DGXQuest Diagnostics Incorporated | $23.6B | $213.45 | $220.57 | +3.3% | Hold | 19.9x | 34 |
TMOThermo Fisher Scientific Inc. | $192.4B | $517.60 | $592.45 | +14.5% | Buy | 20.8x | 42 |
Quick answers to the most common questions about buying SERA stock.
The consensus Wall Street price target for SERA is $5, representing 139.2% upside from the current price of $2.09. With 5 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
SERA has a consensus rating of "Buy" based on 5 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $5 implies 139.2% upside from current levels.
SERA's current price is $2.09 with a consensus target of $5 (139.2% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $5 for SERA, while the most conservative target is $5. The consensus of $5 represents the median expectation. These targets typically reflect 12-month expectations.
SERA is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month SERA stock forecast based on 5 Wall Street analysts shows a consensus price target of $5, with estimates ranging from $5 (bear case) to $5 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on SERA, with a "Buy" consensus rating and $5 price target (139.2% upside). 4 of 5 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
SERA analyst price targets range from $5 to $5, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $5 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.